- International Coffee Organization (ICO) Market Report published on March 7, 2024 highlights alarming price instability challenging the coffee industry
- According to the report, adverse weather conditions, first noted in 2022 and continuing into 2023, will have a negative impact on the outlook for coffee in 2024
- Pluri’s cell-based coffee’s innovative process mimics nature without exploiting it, ensuring consistent quality and high yields, addressing challenges listed in the report
HAIFA, Israel – March 21, 2024 – Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) (“Pluri” or “the Company”), a leading biotechnology company that transforms cells into solutions that promote global wellbeing and sustainability, today addressed the price volatility challenge detailed in the International Coffee Organization’s (ICO) 2024 Market Report (the “Report”) According to the Report, one of the factors creating price volatility is the erratic weather conditions across the globe; from frost in Brazil in 2021 to the El Niño phenomenon expected to worsen heatwaves in Vietnam in 2024. Price instability and cost increases will impact coffee drinkers worldwide, as more than 2 billion cups of coffee are drunk each day, 400 million of them by Americans.
Pluri’s cell-based coffee aims to reduce price instability by moving coffee production into the lab, eliminating the effect of climate change and adverse weather conditions. Pluri recently announced the launch of its cell-based coffee, its proprietary cultured coffee product business, part of its PluriAgtech vertical, addressing the $130 billion coffee industry. The Company’s cell production method grows coffee quickly and reliably in an environmentally sustainable, cost- effective, tightly controlled fully automated manufacturing process that is highly scalable. Pluri’s cell-based coffee is estimated to slash water usage by 98% throughout the entire supply chain and reduce farmland usage by 95% as compared to traditional growing methods.
To learn more about Pluri’s coffee see the recent article titled “Cell-Based Coffee Future-Proofs World’s Favorite Brew” in the leading peer-reviewed journal Nature Biotechnology.
“Pluri’s proprietary method for producing coffee aims to produce a better product with regards to taste, texture, scent, and sustainability,” stated Pluri’s CEO and President Yaky Yanay. “Our solution can help the industry produce coffee in a stable and controlled environment, ensuring consistent availability, price stability and saving everyone’s favorite beverage.”
Learn more about Pluri’s innovative cell-based coffee technology by visiting our website.
About Pluri Inc.
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global well-being and sustainability.
The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of challenges— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective and consistent from batch to batch.
Pluri currently operates in the field of regenerative medicine, food-tech, agtech and biologics and offers CDMO services. Pluri establishes partnerships that leverage the Company’s proprietary 3D cell-based technology across various industries that require effective, mass cell production.
To learn more, visit us at www.pluri-biotech.com or follow Pluri on LinkedIn and X (formerly known as Twitter).
Safe Harbor Statement
This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws.
For example, Pluri is using forward-looking statements when it discusses the potential benefits of its cell- based coffee and that its solution can help the industry produce coffee in a stable and controlled environment, ensuring consistent availability and price stability.
These forward-looking statements and their implications are based on the current expectations of the management of Pluri only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements about Pluri: changes in technology and market requirements; Pluri may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; its products may not be approved by regulatory agencies, its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluri to differ materially from those contemplated in such forward-looking statements.
Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
For a more detailed description of the risks and uncertainties affecting Pluri reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.
Media Contacts
Investors: investor.relations@pluri-biotech.com
Israel Media: Shachar Yental at shacharye@gitam.co.il
U.S. Media: Jessica Daitch at Jessica@quantum-corp.com / Madeline Weirman at Maddie@quantum-corp.com